{"id":"W2937367049","doi":"10.1002/cpt.1477","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz‐Containing Antiretroviral Therapy","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"European and Developing Countries Clinical Trials Partnership; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Human Genome Research Institute; National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research; National Institutes of Health; Partnership for Advanced Computing in Europe AISBL","keywords":"Efavirenz; CYP2B6; Discontinuation; Medicine; Reverse-transcriptase inhibitor; Pharmacogenetics; Adverse effect; Guideline; Pharmacology; Internal medicine; Oncology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Genotype; Cytochrome P450; Biology; CYP1A2; Viral load; Pathology; Genetics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001824847,0.0004083237,0.001003545,0.0001054425,0.0001513437,0.00002911838,0.00018379,0.000337789,0.0006193889],"category_scores_gemma":[0.00002051432,0.0003421197,0.0004084534,0.0001502155,0.00037817,0.00008897496,0.000096658,0.0005329038,0.00009644734],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006186255,"about_ca_system_score_gemma":0.0003961722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002870243,"about_ca_topic_score_gemma":0.000002259975,"domain_scores_codex":[0.9958913,0.0003817232,0.002085842,0.0007773907,0.0002500097,0.000613689],"domain_scores_gemma":[0.9973482,0.001234825,0.0004750646,0.0002941141,0.0003088244,0.0003389318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003324896,0.0009531879,0.7980566,0.00003579519,0.002562932,0.00002533565,0.000170758,0.000001869904,0.008698415,0.0000254808,0.0305367,0.155608],"study_design_scores_gemma":[0.0554689,0.006739206,0.05325948,0.00003187589,0.00319805,0.00003973983,0.0003601251,0.002454052,0.01005583,0.0001244337,0.867654,0.000614336],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.976752,0.002129389,0.0005631167,0.01468244,0.002775147,0.002692999,0.00005044395,0.0001261646,0.0002283306],"genre_scores_gemma":[0.8464287,0.01215326,0.01078644,0.1264201,0.001549793,0.0001388994,0.0003138495,0.0001056692,0.002103296],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8371173,"threshold_uncertainty_score":0.9999031,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1044532864015122,"score_gpt":0.4935270597406963,"score_spread":0.389073773339184,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}